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Background: Reduction in pulmonary exacerbations is an important efficacy endpoint for CF clinical studies. Powering exacerbation endpoints
requires estimation of the future exacerbation incidence in CF study populations, but rates differ across the population.
Methods: We have estimated exacerbation rates for Epidemiologic Study of CF subpopulations stratified by age, FEV1% predicted, sex, weight-
for-age percentile, respiratory signs and symptoms, and history of exacerbation and bacterial culture. Sample sizes required to attain 80% power to
detect exacerbation reductions of 20% to 80% in 1:1 randomized studies of 3 to 12 month duration were determined. Exacerbation treatments with
“any” antibiotic (new oral quinolone, new inhaled antibiotic, or intravenous (IV) antibiotic) and with IV antibiotics were studied.
Results: At all ages, decreased FEV1, female sex, exacerbation history, and Pseudomonas aeruginosa culture history were associated with
increased treatment for exacerbation.
Conclusions: These data should assist investigators in the design of future CF exacerbation studies.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Study design; Pulmonary exacerbation; Sample size1. Introduction
Cystic fibrosis (CF) is a life-shortening genetic disease
characterized by chronic pulmonary bacterial infections, local
inflammation, and progressive loss of pulmonary function [1].
As their lung disease progresses, persons with CF experience
more frequent episodic increases in respiratory signs and
symptoms that require aggressive intervention, commonly
termed pulmonary exacerbations [2–6]. Pulmonary exacerba-
tions adversely impact health-related quality of life [7–9] and
survival [10–13] and lead to significant resource utilization
[14,15]. Despite the lack of a consensus definition of pulmonary
exacerbation, they are clinically meaningful [2,5] and reduction⁎ Corresponding author at: 12520 33rd Street Ct E, Edgewood, WA 98372,
USA. Tel.: +1 253 370 5859.
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doi:10.1016/j.jcf.2011.07.003in exacerbations is an important efficacy endpoint for clinical
studies of chronic CF therapies [16–21].
In order to adequately power CF clinical trials employing
exacerbation as an efficacy endpoint, investigators must be able
to predict the relative risk of exacerbation or median time to
exacerbation for untreated subjects in their study population.
This task is complicated because the risk that an individual will
develop signs and symptoms resulting in exacerbation diagnosis
and treatment is not uniform across the CF population. For
example, diagnoses of pulmonary exacerbation increase with
decreasing pulmonary function [2]. We used data from the
Epidemiologic Study of CF [22] to model relative risk of
exacerbation and median time to exacerbation for different CF
subpopulations. We then estimated the effects of duration of
measure and magnitude of proposed treatment effects on sample
size requirements for randomized clinical trials using relative
risk of pulmonary exacerbation as an efficacy endpoint.d by Elsevier B.V. All rights reserved.
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Data were obtained from ESCF, a prospective, encounter-
based, multicenter, observational study designed to evaluate the
natural history of CF patients in North America from 1994 to
2005 [22]. Informed consent was obtained based on decisions
by local human subjects review boards. Pulmonary function test
results were reported as measured values and converted to
percent predicted using reference equations from Wang et al.
[23] for females through age 15 and males through age 17, and
Hankinson et al. [24] at older ages.
To be included in this analysis, patients had to have had a
routine (i.e., stable) clinic encounter (index visit) at least twelve
months after enrollment in ESCF during which pulmonary
function testing was performed within ±7 days of the visit and no
treatment for exacerbation had been administered within
±14 days. In addition, the patient had to have had at least one
routine clinic encounter within the calendar year prior to the index
visit (the baseline period) and to have had at least 4 encounters
spaced roughly quarterly (±45 days) within a 13.5 month follow
up period after the index visit. Patients could be included more
than once in the analysis provided that their subsequent index
visits did not occur during the follow up period from previous
analyses. Patients missing their date of ESCF enrollment, date of
birth, or sex were excluded from the analysis.
Two definitions of treatment associated with pulmonary
exacerbations were employed in analyses: intravenous (IV)
treatment (treatment with any IV antibiotic) and “any” treatment
(defined as treatment with any IV antibiotic, any new inhaled
antibiotic, or any new oral fluoroquinolone) within a −7 to
+28 day period around an encounter. The first treatment for
pulmonary exacerbation after the index visit during the follow up
period was characterized for patient subgroups stratified at their
index visit by age in years (b6, 6–12, 13–17, 18–24, or ≥25),
FEV1% predicted (≥100, 70–b100, 40–b70, and b40), sex,
weight-for-age percentile (WFA) (b25th and≥25th), presence of
signs and symptoms (daily cough, daily sputum production,
clubbing, crackles, or wheeze), number of IV treatments for
exacerbation during the baseline period (0, 1, 2, and ≥3), and
presence ofPseudomonas aeruginosa, Staphylococcus aureus, or
Haemophilus influenzae on respiratory tract culture during the
baseline period (any positive, no positive). P. aeruginosa culture
history during the baseline year was further stratified by modified
Leeds criteria [25] as either “chronic” infection (2 ormore cultures
and N50% of cultures positive for P. aeruginosa), “intermittent”
infection (2 or more cultures and ≤50% positive), or “indeter-
minate” infection (one positive culture). Patients with no record of
IV antibiotic treatment for an exacerbation during the baseline
period were considered to have had zero exacerbations, and
bacterial culture results obtained at the index visit were used for
patients lacking culture results during the baseline period.
Analyses were performed using SAS version 9.1 (SAS
Institute, Inc., Cary, NC). Median times to treatment for
exacerbation during the follow up period were determined for
all patient subgroups using Kaplan–Meier estimates generated
from the SAS LIFETEST procedure. We also determined
proportions of patients treated at least once for exacerbations at3, 6, 9, and 12 months after the index visit. We used this
information to calculate the number of subjects per arm required
in 1:1 randomized controlled studies to attain 80% power for a
variety of treatment effect sizes, study durations, and patient
subgroups based on a log-rank test using the SAS POWER
procedure assuming a two-sided alpha of 0.05. Reductions of
20%, 30%, 40%, 50%, 60%, 70% and 80% in the proportion of
subjects treated for pulmonary exacerbation were evaluated for
studies of 3, 6, 9, and 12 month durations using both exacerbation
treatment definitions. Sample sizes were calculated for patient
subgroups by age, FEV1, sex, WFA, signs and symptoms,
previous exacerbation history, and bacterial culture status.
3. Results
A total of 39,326 unique analysis periods were captured
among 16,082 eligible ESCF patients, with 10,018 patients
contributing at least twice to analyses. Distributions of patients
by age, pulmonary function, and other variables are provided in
Table 1. Due to inclusion criteria, none of the 9653 patients
under 6 years of age were less than 1 year of age at their index
visit; the group had a median age of 3.69 years.
During the follow up period, patients were much more likely
to be treated with “any” antibiotic (including oral fluoroquino-
lones and inhaled antibiotics) than to be treated with IV
antibiotics for exacerbation. The median time to receive “any”
treatment for all patients was 294 days, with 55.0% having been
treated at least once during the follow up period. In contrast,
only 34.1% of patients had been treated at least once with IV
antibiotics during the same period.
Patient stratification identified subgroups at greater risk for
exacerbation treatment during the follow up period. Table 2
shows median times to “any” antibiotic treatment for different
subgroups (data not shown for IV treatment), and Table 3 shows
the percentages of patients treated with “any” and with IV
antibiotics during the follow up period. Likelihood of treatment
was strongly influenced by FEV1 as measured at the index visit.
Patients b6 years of age and patients 6–12 and 13–17 years of
age with FEV1≥100% predicted had estimated median times to
“any” treatmentN365 days: only 35.3%, 36.5%, 46.1%, respec-
tively, were treated at least once during the one-year follow up
period (Tables 2 and 3). Median time to IV antibiotic treatment
was less than 6 months for patients with FEV1b40% predicted
and about 9 months for patients with FEV1 between 40 andb70%
predicted; other patients with higher FEV1% predicted had
median times to IV treatment of more than 12 months. Older
patients tended to have lower median times to treatment with
“any” antibiotics than younger patients (Table 2), with the
exception that patients ≥25 years old at their index visit had a
slightly longer median time to treatment with any antibiotic
(155 days) than patients 18 to 24 years old (143 days).
Females were consistently more likely to receive antibiotic
treatment than males irrespective of treatment criteria or
subgroup studied (Tables 2 and 3). Overall, patients with
lower WFA at their index visit were at a modestly higher risk for
treatment, with the greatest differences observed among patients
with FEV1b70% predicted and those b6 years old. Patients
Table 1
Numbers of patients contributing to subgroup analyses.
FEV1 range (% predicted)
All Ageb6 yr ≥100 70 to
b100
40 to
b70
b40
All patients 39,326 9653 5573 12,752 7991 3357
Age group
6–12 yr 13,398 – 4038 6926 2117 317
13–17 yr 7698 – 1293 3686 2171 548
18–24 yr 4280 – 180 1364 1823 913
≥25 yr 4297 – 62 776 1880 1579
Sex, male 19,930 4827 2998 6497 3761 1847
WFA percentile a
b25th 18,228 3911 1791 5469 4643 2414
≥25th 20,988 5711 3772 7255 3320 930
Signs and symptoms a
Daily cough 18,016 2460 1683 5605 5457 2811
Daily sputum 11,087 640 678 3094 4156 2519
Clubbing 20,190 2139 2356 6935 5880 2880
Crackles 6739 392 221 1338 2619 2169
Wheeze 1778 288 148 483 500 359
Pulmonary exacerbation history b
None 24,777 7149 4566 8793 3395 874
One 8438 1700 757 2703 2335 943
Two 3384 504 167 816 1163 734
Three or more 2727 300 83 440 1098 806
P. aeruginosa culture history c
All negative 15,572 5761 2846 4885 1647 433
Any positive 20,269 2732 2295 6749 5765 2728
Indeterminate d 4818 685 607 1797 1216 513
Intermittent e 4155 1311 626 1303 684 231
Chronic f 11,296 736 1062 3649 3865 1984
a As recorded at the index visit.
b Number of pulmonary exacerbations treated with IV antibiotics in the
12 months prior to the index visit.
c Recorded in the 12 months prior to the index visit.
d Only one culture result reported.
e ≤50% of cultures positive.
f N50% of cultures positive.
Table 2
Median time (days) to treatment during the follow up period with “any”
antibiotics for a pulmonary exacerbation by patient subgroup.
FEV1 range (% predicted)
All Ageb6 yr ≥100 70 to
b100
40 to
b70
b40
All patients 294 (N365) a (N365) 299 147 112
Age group
6–12 yr 364 – (N365) 365 179 98
13–17 yr 202 – (N365) 258 133 96
18–24 yr 143 – 312 203 127 98
≥25 yr 155 – 302 252 161 125
Sex
Male 329 (N365) (N365) 343 168 120
Female 266 (N365) (N365) 268 133 98
WFA percentile b
b25th 238 (N365) (N365) 299 133 106
≥25th 357 (N365) (N365) 299 168 121
Signs and symptoms b
Daily cough 189 (N365) 364 224 133 107
Daily sputum 154 317 280 210 128 108
Clubbing 203 (N365) (N365) 266 135 110
Crackles 133 273 (N365) 203 121 103
Wheeze 218 (N365) (N365) 308 136 126
Pulmonary exacerbation history c
None 398 (N365) (N365) (N365) 231 189
One 193 (N365) 280 193 147 124
Two 119 259 168 121 98 102
Three or more 77 168 134 84 69 65
P. aeruginosa culture history d
All negative (N365) (N365) (N365) (N365) 197 139
Any positive 187 (N365) 316 216 131 105
Indeterminate e 222 (N365) 308 252 175 133
Intermittent f 282 (N365) (N365) 271 159 91
Chronic g 147 268 276 189 119 98
a When time N365 days, less than half of subjects were treated with “any”
antibiotics during the follow up period.
b As recorded at the index visit.
c Number of pulmonary exacerbations treated with IV antibiotics in the
12 months prior to the index visit.
d Recorded in the 12 months prior to the index visit.
e Only one culture result reported.
f ≤50% of cultures positive.
g N50% of cultures positive.
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production, clubbing, crackles, or wheeze at their index visits
generally were more often treated with antibiotics than the
entire population (“all patients” in Table 3), an exception being
patients with wheeze and lower FEV1.
Strong positive relationships were observed across all lung
disease stages between history of exacerbation in the baseline year
and antibiotic treatment during the follow up period (Table 3).
History of any respiratory culture positive forP. aeruginosa in the
baseline period increased the probability of treatment for
exacerbation during the follow up period among all subgroups.
The median time to treatment with “any” antibiotic for patients
with a positive P. aeruginosa culture was about 6 months, and
over two-thirds were treated during the follow up period,
compared with less than 40% of patients with no positive
P. aeruginosa cultures in the prior year (Tables 2 and 3).
Similarly, 44.6% of patients with a positive P. aeruginosa culture
in the prior year were treated with IV antibiotics in the follow up
period, compared to 22.5% of patients with no positive cultures
during the period. Within the P. aeruginosa culture-positive
subpopulation, patients identified as having chronic infection intheir baseline year generally had shortermedian times to treatment
with “any” antibiotics than other patients (Table 2), and were
uniformly more likely to be treated with IV or “any” antibiotics
than were intermittently infected patients (Table 3). Patients with
history of S. aureus culture in the baseline period had only
modestly lower probability of treatment in the follow up period
relative to the entire population (less than a 2% difference).
History ofH. influenzae culture in the baseline period had a more
pronounced negative influence, with “any” antibiotic treatment
lower than “all patients” by about 10 percentage points and IV
antibiotic treatment lower by about 7 percentage points. This
effect was most pronounced in children less than 6 years old and
older patients with less advanced lung disease (data not shown).
Sample sizes required to attain 80% power to detect a given
reduction in treatment for exacerbation in a 1:1 randomized
study of all patients varied as a function of antibiotic treatment
definition (“any” antibiotics or IV antibiotics) and duration of
Table 3
Percentage of patients treated with either “any” antibiotics or IV antibiotics during the follow up period by patient subgroup.
FEV1 range (% predicted)
All patients Ageb6 yr ≥100 70 to b100 40 to b70 b40
“Any” IV “Any” IV “Any” IV “Any” IV “Any” IV “Any” IV
All patients 55.0 34.1 35.3 18.8 39.5 16.0 55.0 29.2 76.8 57.0 85.7 72.7
Age group
6–12 yr 49.8 27.6 – – 36.5 14.5 49.2 25.2 71.8 54.1 84.5 72.5
13–17 yr 65.5 41.0 – – 46.1 19.9 60.7 32.0 79.4 59.0 89.0 79.8
18–24 yr 76.0 56.1 – – 54.7 21.9 65.6 39.5 80.6 61.7 86.4 76.5
≥25 yr 75.8 54.6 – – 51.6 12.9 60.5 33.6 75.7 53.1 84.3 68.2
Sex
Male 52.3 31.2 33.3 17.9 37.9 14.4 51.7 25.2 73.6 53.2 84.1 69.2
Female 57.8 37.1 37.3 19.8 41.4 17.7 58.4 33.3 79.6 60.3 87.6 77.0
WFA percentile a
b25th 60.5 40.9 39.0 23.3 40.6 17.1 55.2 30.1 78.9 59.9 86.8 74.9
≥25th 50.2 28.2 32.7 15.8 39.0 15.4 54.7 28.4 74.0 53.1 82.6 67.1
Signs and symptoms a
Daily cough 67.9 46.7 44.8 26.2 49.5 21.5 62.6 36.3 79.8 60.4 86.8 74.2
Daily sputum 74.8 54.8 52.9 33.3 57.5 25.7 65.9 40.0 80.3 61.9 87.0 74.6
Clubbing 65.5 43.5 43.8 24.0 42.7 16.7 59.5 32.2 79.3 59.7 86.4 74.0
Crackles 78.1 60.9 58.0 41.6 46.0 25.6 67.0 42.7 82.3 64.8 86.7 74.5
Wheeze 61.5 43.2 40.0 27.3 40.2 18.5 53.6 31.7 75.2 54.3 79.3 66.3
Pulmonary exacerbation history b
None 42.4 19.4 28.9 12.7 34.4 11.1 46.2 19.3 64.0 37.8 72.1 49.3
One 68.9 47.4 48.6 30.3 58.0 32.6 69.3 43.1 80.2 60.1 85.5 71.0
Two 82.8 67.9 61.1 45.3 73.2 48.7 82.1 61.3 89.4 76.4 90.2 81.9
Three or more 92.0 84.4 68.9 55.5 81.4 69.4 93.0 81.9 95.6 89.0 96.2 91.8
P. aeruginosa culture history c
All negative 38.4 22.5 29.5 16.1 29.2 12.8 41.4 22.3 66.4 50.2 77.9 66.0
Any Positive 69.1 44.6 48.4 25.1 53.0 20.2 65.3 35.0 80.8 60.5 87.8 75.1
Indeterminate d 63.9 36.3 45.2 22.9 53.5 20.2 61.7 31.3 74.8 50.0 82.8 64
Intermittent e 56.5 32.8 44.6 21.7 44.7 17.9 58.2 38.9 76.3 55.7 86.9 77.3
Chronic f 75.9 52.5 58.3 33.3 57.6 21.6 69.6 50.0 83.5 64.6 89.1 77.7
a As recorded at the index visit.
b Number of pulmonary exacerbations treated with IV antibiotics in the 12 months prior to the index visit.
c Recorded in the 12 months prior to the index visit.
d Only one culture result reported.
e ≤50% of cultures positive.
f N50% of cultures positive.
Fig. 1. Effects of treatment definition and duration of observation on sample sizes
required to detect a given treatment effect in a randomized controlled study. Sample
sizes per arm required to assure 80% power to detect reductions in exacerbation
treatment (as hazard ratios) in 1:1 randomized studies of 3 month (clear lines),
6 month (light gray lines), 9 month (dark gray lines), or 12 month (black lines)
durations. Results for exacerbation treatment defined as administration of “any”
antibiotics are shown as solid lines and those for treatment defined as administra-
tion of IV antibiotics are shown as dashed lines.
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with IV antibiotics than “any” antibiotics at any given time
during the follow up, correspondingly more subjects are
required in order to adequately power randomized studies
using IV treatment than studies using “any” antibiotic treatment
as endpoints (Fig. 1). Similarly, the increase in the proportion of
patients treated for exacerbation as a function of time elapsed
from their index visit results in fewer subjects per arm being
required to detect a given treatment effect as study observation
periods increase from 3 months to 1 year (Figs. 1, 2). Studies
limited to patient subgroups at greater risk for exacerbation
(e.g., with lower FEV1% predicted at their index visit, prior
history of exacerbation or positive P. aeruginosa culture
history) require fewer subjects per arm to detect a given
treatment effect than studies in patients without these risk
factors (Table 4 and Fig. 2). Numbers of subjects stratified by
subgroups required per study arm to attain 80% power to detect
a 40% reduction in the risk of treatment (i.e., hazard ratio=0.6)
with “any” antibiotics and IV antibiotics for exacerbation in a
1:1 randomized 6 month study are provided in Table 4.
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Fig. 2. Sample sizes required per study arm to retain 80% power to detect a 40%
reduction in risk of treatment for exacerbation as a function of lung disease stage
and study duration. Panel A: sample sizes required to detect a reduction in
treatment with “any” antibiotics. Panel B: sample sizes required to detect a
reduction in treatment with IV antibiotics. Note that the scale of the vertical axis
of panel B is twice the magnitude of that of panel A.
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There is little question that chronic therapies capable of
reducing the incidence of CF exacerbations have the potential to
reduce health care costs [14,15], improve patient quality of life
[7–9], spare loss of lung function [26], and possibly improve
survival [10–13]. However, the use of change in risk of
pulmonary exacerbation as an efficacy endpoint for randomized
CF trials is challenging. For example, powering of trials em-
ploying risk of exacerbation as an endpoint requires knowledge
of the underlying risk of exacerbation in the intended study
population, but risk of exacerbation is not uniform across the CF
population [2].
In practice, many clinical trials have employed physician
intervention in their definition of an exacerbation. We have
analyzed data collected over 10 years from a large set of CF
patients in ESCF to characterize how patient characteristics affect
the probability of treatment with antipseudomonal antibiotics for
exacerbation and how they affect the corresponding sample sizerequirements for studies using exacerbation treatment as an
efficacy endpoint. We have reported sample sizes required to
attain 80% power to detect a 40% reduction in treated
exacerbations over a 6 month observation period (Table 4). A
treatment benefit of this magnitude (i.e., hazard ratio=0.6) is
consistent with reductions reported in past CF trials of dornase
alfa (relative risk=0.63 for bid use, [16]), inhaled tobramycin
(relative risk=0.64, [17]), chronic azithromycin (relative
risk=0.65, [18]), and inhaled aztreonam (relative risk=0.55,
[21]). The choice of a 6 month observation period was a
pragmatic one, in that studies of shorter duration require
substantially more subjects to attain adequate statistical power
(Fig. 1).
Although our data are useful for estimating the likelihood of
different subgroups being treated for exacerbation over time, the
absolute sample sizes reported in Table 4 are dependent upon
several conditions that may not be met in future clinical trials.
We have reported results using two indirect measures of
pulmonary exacerbation: treatment with “any” antibiotics
(defined as new treatment with oral quinolones or inhaled
antibiotics or treatment with IV antibiotics) and treatment with
IV antibiotics. These measures have been incorporated into
exacerbation definitions in the past [16–18,27], but it should be
noted that these treatments tend to be administered in the belief
that exacerbation symptoms are caused by P. aeruginosa. In this
context, our observation that negative, intermittent, or chronic
P. aeruginosa culture histories in the baseline period are
associated with different probabilities of treatment with
antipseudomonal antibiotics for exacerbation (Table 3) should
not be surprising. The extent to which different culture histories
actually affect presentation of signs and symptoms of
exacerbation or simply increase the probability of being treated
with antipseudomonal antibiotics during exacerbation is not
clear. Importantly, the proportion of patients with a history of
positive P. aeruginosa culture increases with age (Table 1).
Clinicians may be less suspicious of P. aeruginosa in younger
patients in the absence of definitive culture data, in which case
using antipseudomonal antibiotic treatment as a measure would
likely underestimate exacerbation rates. Use of an exacerbation
definition requiring the presence of a constellation of specific
clinical signs and symptoms in addition to specific interventions
[16] would presumably reduce the overall event rate, thereby
increasing sample size estimates. In contrast, a definition
consisting solely of presentation of signs and symptoms and for
which intervention is not a requirement [28] would likely
increase observed exacerbation rates and correspondingly
reduce required sample sizes. The use of patient diaries and
patient-reported outcome measures [29,30] are attractive
approaches to avoiding the complication of defining exacerba-
tions based on specific clinical interventions. These approaches
are likely to increase event rates and thus reduce required
sample sizes for clinical trials.
Observed exacerbation rates may be affected not only by the
exacerbation definition, but also by the frequency of encounter.
Currently, identification of exacerbation occurs at clinic encoun-
ters, so an increased encounter frequency may increase the
frequency of exacerbations. To be included in the analysis,
Table 4
Subjects required per arm to detect a 0.6 hazard ratio in a 6-month controlled study using either treatment with “any” or IV antibiotics for exacerbation as an endpoint.
FEV1 range (% predicted)
All patients Ageb6 yr ≥100 70 to b100 40 to b70 b40
“Any” IV “Any” IV “Any” IV “Any” IV “Any” IV “Any” IV
All patients 202 355 360 745 332 959 212 450 129 195 105 138
Age group
6–12 yr 239 473 – – 377 1031 248 556 143 213 103 139
13–17 yr 161 288 – – 261 851 188 401 121 183 95 121
18–24 yr 127 191 – – 214 630 157 288 119 175 102 127
≥25 yr 134 204 – – 197 686 193 389 136 216 112 152
Sex
Male 217 398 374 754 348 1101 234 535 139 217 111 152
Female 188 320 347 736 315 833 193 386 121 179 99 124
WFA percentile a
b25th 175 283 315 572 317 868 211 429 123 183 103 131
≥25th 231 455 399 939 339 1010 214 469 138 214 113 159
Signs and symptoms a
Daily cough 151 241 260 480 242 666 175 336 121 180 103 134
Daily sputum 132 198 206 352 207 514 164 298 119 174 103 132
Clubbing 160 263 272 528 305 887 192 392 123 185 103 134
Crackles 123 177 192 279 273 615 163 299 114 168 102 132
Wheeze 165 264 315 557 324 912 197 376 126 190 116 163
Pulmonary exacerbation history b
None 305 778 471 1258 406 1529 282 807 185 370 152 267
One 155 260 251 436 204 439 155 294 126 200 111 154
Two 109 150 181 268 133 252 113 173 94 124 96 120
Three or more 86 103 135 188 117 168 88 111 81 96 78 87
P. aeruginosa Culture History c
All negative 327 608 458 901 496 1321 302 620 162 241 127 166
Any positive 150 257 243 535 229 708 170 362 120 179 101 131
Indeterminate d 176 358 271 679 240 740 190 482 140 244 120 170
Intermittent e 198 374 273 643 290 825 197 418 131 199 99 121
Chronic f 130 207 187 355 199 639 154 309 112 162 97 125
a As recorded at the index visit.
b Number of pulmonary exacerbations treated with IV antibiotics in the 12 months prior to the index visit.
c Recorded in the 12 months prior to the index visit.
d Only one culture result reported.
e ≤50% of cultures positive.
f N50% of cultures positive.
458 D.R. VanDevanter et al. / Journal of Cystic Fibrosis 10 (2011) 453–459patients were required to have at least 4 routine clinic encounters
during a year of observation, an encounter frequency consistent
with current CF practice guidelines [4]. However, controlled
clinical trials are often designedwithmore frequent (e.g.,monthly)
study visits, and thus observed rates of exacerbation might be
higher and required sample sizes correspondingly lower than our
predictions based on quarterly encounter data. For example,
52.0% of placebo subjects were treated with IV antibiotics during
the 6 month inhaled tobramycin studies, which included at least
8 clinic encounters after treatment initiation [17]. We analyzed
6098 ESCF patients employing similar inclusion criteria
(≥6 years old, FEV1 between 25 and 75% predicted, and chronic
P. aeruginosa culture status in the prior year), but our requirement
of only 4 quarterly clinic encounters in the follow up period
resulted in only 46.1% of these patients treated with IV antibiotics
for exacerbation in the 6 months following the index visit. This
modest difference in event ratesmay result in part fromdifferences
in encounter frequency.
Even with these caveats, our analyses should be of value to
clinical investigators using exacerbation as an efficacy endpointin CF clinical trials. Despite consistent incremental improve-
ment in the overall health of the CF population [27,31], rates at
which patients are treated with antibiotics for pulmonary
exacerbations have been remarkably constant over the past
two decades [31], suggesting that registry data from the recent
past can be useful in predicting future treatment rates. Our data
indicate how inclusion/exclusion criteria might be adjusted to
select subjects at greater risk for exacerbation (e.g., subjects that
are older, have more advanced lung disease, or have a recent
history of exacerbation). Conversely, our data suggest that
detecting an impact on exacerbation rate in some subpopula-
tions (e.g., subjects with early lung disease) may prove prob-
lematic due to sample size requirements.
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